The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (ILD)

Publications

Capron T, Botto G, Roujon JJ, Miltgen J, Berard H

Drug-induced interstitial lung disease: Indictment for apixaban.

Respiratory medicine and research 2023 May 19;84;101024 — 2023 May 19 — 101024

Yun WS, Kim SW, Jung LY

A case of apixaban-associated idiopathic interstitial pneumonia.

Cardiology journal 2022;29;364-365 — 2022 — 364-365

Raschi E, Fusaroli M, Diemberger I, Poluzzi E

Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance.

Drug safety 2020 11;43;1191-1194 — 2020 11 — 1191-1194

Tomari S, Homma K, Noguchi T, Aiba T, Matsuki T, Suzuki R, Koga M, Takigami M, Tagawa H, Hashimoto T, Toyoda K

Development of Interstitial Lung Disease after Initiation of Apixaban Anticoagulation Therapy.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2016 Jul;25;1767-1769 — 2016 Jul — 1767-1769